Skip to main content

fampridine (Fampyra®)

 

Following a full submission

AWMSG advice

Status: Recommended

Fampridine (Fampyra®) is recommended as an option for use within NHS Wales for the improvement of walking in adult patients with multiple sclerosis with walking disability (Expanded Disability Status Scale [EDSS] 4 to 7). This recommendation applies only in circumstances where the approved Wales Patient Access Scheme (WPAS) is utilised or where the list/contract price is equivalent or lower than the WPAS price.

 Final Recommendation: fampridine (Fampyra) 3942 (PDF, 188Kb)
 Appraisal Report: fampridine (Fampyra) 3942 (PDF, 297Kb)

Medicine details

Medicine name fampridine (Fampyra®)
Formulation 10 mg prolonged-release tablet
Reference number 3942
Indication

Improvement of walking in adult patients with multiple sclerosis with walking disability (Expanded Disability Status Scale 4–7)

Company Biogen Idec Ltd
BNF chapter Central nervous system
Submission type Full
Status Recommended
Advice number 1919
NMG meeting date 06/11/2019
AWMSG meeting date 11/12/2019
Date of issue 12/12/2019
Commercial arrangement WPAS